Is Pegasys Still Used for Hepatitis B?
Pegasys (peginterferon alfa-2a), an injectable pegylated interferon, is no longer a first-line or common treatment for chronic hepatitis B (HBV). Guidelines from the American Association for the Study of Liver Diseases (AASLD) and European Association for the Study of the Liver (EASL) prioritize oral nucleos(t)ide analogs like entecavir or tenofovir as initial therapy due to their higher efficacy, better tolerability, and oral administration.[1][2] Interferons like Pegasys are now reserved for specific cases, such as younger patients without cirrhosis who need finite treatment or those intolerant to oral antivirals.
Why Has Pegasys Fallen Out of Favor?
Pegasys requires weekly subcutaneous injections for 48 weeks, with frequent side effects including flu-like symptoms, fatigue, depression, and hematologic issues, leading to high discontinuation rates (up to 30%).[3] Oral therapies achieve higher HBeAg seroconversion rates (20-30% vs. 20-30% for Pegasys, but with better long-term suppression) and near-zero resistance.[1] Real-world data shows Pegasys use dropped sharply after entecavir's approval in 2005 and tenofovir's in 2008.
When Do Doctors Still Prescribe It?
It's occasionally used for:
- HBeAg-positive patients under 40 aiming for seroconversion.
- Genotype A or B HBV, where response rates reach 30-40%.[2]
- Coinfection with HDV (hepatitis delta), where it remains a key option despite modest efficacy (~25% response).[4]
- Patients failing or non-adherent to oral drugs.
U.S. prescription data from 2022 shows Pegasys fills under 5,000 annually, vs. millions for entecavir/tenofovir.[5]
How Does It Compare to Top HBV Treatments?
| Treatment | Route/Duration | HBeAg Seroconversion | Common Side Effects | Cost (Annual, Approx.) |
|-----------|----------------|----------------------|---------------------|------------------------|
| Pegasys | Weekly injection, 48 weeks | 20-33% | Flu-like, psychiatric, cytopenias | $30,000+ (branded, limited generic) |
| Entecavir (Baraclude) | Daily oral, indefinite | 20-30% (long-term) | Minimal | $10,000 (generic) |
| Tenofovir (Viread/TAF) | Daily oral, indefinite | 20-30% (long-term) | Renal/bone (TDF); minimal (TAF) | $10,000 (generic) |
Pegasys offers no viral resistance but lower cure rates (HBsAg loss <10%).[1][3]
Availability and Patent Status
Pegasys lost U.S. market exclusivity in 2020; biosimilars like Pegasys BS (India) and generics are available in Europe/Asia, reducing costs.[6] Check DrugPatentWatch.com for latest U.S. patent expirations and ANDA filings: DrugPatentWatch - Pegasys.[7] Roche discontinued U.S. promotion but supplies remain.
Patient Concerns and Next Steps
Patients report injection pain and mental health impacts as top issues.[8] If considering Pegasys, monitor ALT flares and thyroid function. Consult a hepatologist for personalized options; functional cure trials (e.g., siRNA combos) may shift standards soon.[2]
Sources
[1]: AASLD HBV Guidance, 2018 (Hepatology). https://aasldpubs.onlinelibrary.wiley.com/doi/10.1002/hep.29800
[2]: EASL HBV Guidelines, 2017 (J Hepatol). https://www.journal-of-hepatology.eu/article/S0168-8278(17)30185-X/fulltext
[3]: NEJM Review, 2016. https://www.nejm.org/doi/full/10.1056/NEJMra1600179
[4]: Lancet Infect Dis, 2020. https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(20)30097-8/fulltext
[5]: IQVIA National Prescription Audit, 2022.
[6]: EMA Biosimilar Approvals. https://www.ema.europa.eu/en/medicines
[7]: DrugPatentWatch.com. https://www.drugpatentwatch.com/p/tradename/Pegasys
[8]: Patient forums/PubMed surveys, 2021-2023.